Dear Member,

We understand that delivering a consistent New Medicine Service (NMS) requires balancing clinical expertise with operational pressure. However, targeting high-risk patient groups remains the most effective way to improve adherence outcomes and demonstrate the value of community pharmacy.

As we reach Week 5 of our clinical series, we are shifting our focus to "Technique and Tolerance." These are therapy areas where the method of administration (eye drops) or the tolerability of side effects (dry mouth) are the primary barriers to adherence, often leading to early discontinuation before therapeutic benefits are realized.

The "Technique & Tolerance" Focus

This week, we are providing expert-level support sheets for:

• Glaucoma (The Silent Thief): Bridging the gap between a symptom-free disease and a treatment that stings. We focus on the critical role of "Punctal Occlusion" to maximize efficacy while minimizing systemic risks like bradycardia or bronchospasm.
• Urinary Incontinence & Retention (LUTS): Managing the "Anticholinergic Gap"—where side effects like dry mouth occur immediately, but bladder control takes weeks. We also cover the "Triple Whammy" of confusion in elderly patients and the delayed onset of 5-ARIs in BPH.

Why focus on these this week? Both conditions have notoriously high non-adherence rates driven by physical discomfort. Glaucoma patients often stop because "the drops hurt more than the disease," while OAB patients quit because dry mouth feels worse than urgency. Your consultation is the intervention that normalizes these sensations and corrects the administration techniques that cause them.

Please review the attached guides and use them to refine your conversations and support your patients through these difficult initiation periods.

Mandatory Clinical Disclaimer: Pharmacists must always verify information against current sources. The materials provided in this series are visual training aids designed for educational purposes only. They should not be relied upon to make clinical decisions. Professional clinical judgement must be exercised at all times, and the latest SPC, BNF, and NICE guidelines must be consulted. The authors accept no liability for clinical errors.

Series Catch-Up: Previous Modules Sent to Date

To ensure your team has a complete clinical library, here is a recap of the high-impact modules we have covered in this series so far:

• Lipid Management (Hypercholesterolaemia): Bridging the gap between "invisible" protection and the "Nocebo effect" of muscle pain.
• Osteoporosis (Bisphosphonates): Engineering adherence for complex administration rules and preventing "The Silent Fracture.”
• Heart Failure: Focus on the "Initiation Titration" and monitoring for electrolyte imbalances with ACEi/Beta-Blockers.
• Epilepsy: Managing the "Bioequivalence" of different brands and the critical importance of a zero-miss dose policy.
• Parkinson’s: Engineering the "On/Off" phenomenon and the necessity of strict timing for Levodopa doses.
• Hypertension: Navigating the "Triple Whammy" (ACEi + Diuretic + NSAID) and managing the ACEi dry cough.
• Anticoagulation: Safety-netting for major bleeds and explaining the short half-life of DOACs compared to Warfarin.
• Depression: Bridging the "Suicide Window"—the dangerous period where physical energy returns before mood improves.

Regards,

PharmaPlus